Analyst firms · Needham · DAWN
Needham DAWN price target and rating history
Day One Biopharmaceuticals Inc. (DAWN) · Health Care
Needham rates Day One Biopharmaceuticals Inc. (DAWN) Buy with a $33 price target, as of its latest action on Oct 9, 2024. It has published 3 rating actions on DAWN since December 2022, including 0 upgrades and 0 downgrades.
- Current rating
- Buy
- Price target
- $33
- Median target, all firms
- Too few
- Actions on DAWN
- 3
Needham price target on DAWN
Every Needham rating on DAWN
- Oct 9, 2024
- Apr 24, 2024
- Dec 14, 2022
How other firms rate DAWN
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| H.C. Wainwright | Neutral | $21.50 | Mar 10, 2026 |
| TD Cowen | Buy | $34 | Jan 13, 2026 |
Questions about Needham and DAWN
- What is Needham's price target for DAWN?
- Needham's latest stated price target for Day One Biopharmaceuticals Inc. (DAWN) is $33, from its action on Oct 9, 2024.
- What is Needham's rating on DAWN?
- Needham rates DAWN Buy, a bullish rating, as of Oct 9, 2024.
- When did Needham last change its view on DAWN?
- On Oct 9, 2024, Needham raises its price target to $33 from $32, keeps Buy.
More DAWN rating histories
All Needham ratingsDAWN news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.